%PDF-1.6
%
1 0 obj
<>/OCGs[12 0 R 13 0 R 14 0 R 15 0 R]>>/OutputIntents[<>]/PageLabels 18 0 R/Pages 3 0 R/Type/Catalog/ViewerPreferences<>>>
endobj
2 0 obj
<>stream
2021-02-15T11:31:33+09:00
2021-02-15T11:31:34+09:00
2021-02-15T11:31:34+09:00
Adobe InDesign CC 14.0 (Windows)
1
uuid:7f8e738b-fbfb-4213-a705-75b8f4a970f5
adobe:docid:indd:2639da3c-a4ea-11e3-8cd5-a06b3b5f3376
xmp.id:4843fe8f-7ab4-9c4a-a43e-01c5dab0d6bd
proof:pdf
xmp.iid:a92f318a-e45c-5f42-a090-948d89b0f4c5
adobe:docid:indd:2639da3c-a4ea-11e3-8cd5-a06b3b5f3376
1
adobe:docid:indd:2639da3c-a4ea-11e3-8cd5-a06b3b5f3376
default
converted
from application/x-indesign to application/pdf
Adobe InDesign CC 14.0 (Windows)
/
2021-02-15T11:31:33+09:00
application/pdf
06KMJ-2020-02小橋論文.indd
Adobe PDF Library 15.0
False
PDF/X-4
PDF/X-4
endstream
endobj
18 0 obj
<>
endobj
3 0 obj
<>
endobj
5 0 obj
</LastModified/NumberofPages 1/OriginalDocumentID/PageUIDList<0 124>>/PageWidthList<0 515.906>>>>>>/Resources<>/Font<>/ProcSet[/PDF/Text]/Properties<>/XObject<>>>/TrimBox[8.50394 8.50394 524.409 737.008]/Type/Page>>
endobj
6 0 obj
</LastModified/NumberofPages 1/OriginalDocumentID/PageUIDList<0 358>>/PageWidthList<0 515.906>>>>>>/Resources<>/Font<>/ProcSet[/PDF/Text]/Properties<>/XObject<>>>/TrimBox[8.50394 8.50394 524.409 737.008]/Type/Page>>
endobj
7 0 obj
</LastModified/NumberofPages 1/OriginalDocumentID/PageUIDList<0 25560>>/PageWidthList<0 515.906>>>>>>/Resources<>/Font<>/ProcSet[/PDF/Text]/Properties<>/XObject<>>>/TrimBox[8.50394 8.50394 524.409 737.008]/Type/Page>>
endobj
8 0 obj
</LastModified/NumberofPages 1/OriginalDocumentID/PageUIDList<0 26198>>/PageWidthList<0 515.906>>>>>>/Resources<>/ExtGState<>/Font<>/ProcSet[/PDF/Text/ImageC/ImageI]/Properties<>/XObject<>>>/TrimBox[8.50394 8.50394 524.409 737.008]/Type/Page>>
endobj
9 0 obj
</LastModified/NumberofPages 1/OriginalDocumentID/PageUIDList<0 21002>>/PageWidthList<0 515.906>>>>>>/Resources<>/ExtGState<>/Font<>/ProcSet[/PDF/Text/ImageC/ImageI]/Properties<>/XObject<>>>/TrimBox[8.50394 8.50394 524.409 737.008]/Type/Page>>
endobj
10 0 obj
</LastModified/NumberofPages 1/OriginalDocumentID/PageUIDList<0 27077>>/PageWidthList<0 515.906>>>>>>/Resources<>/Font<>/ProcSet[/PDF/Text]/Properties<>/XObject<>>>/TrimBox[8.50394 8.50394 524.409 737.008]/Type/Page>>
endobj
11 0 obj
</LastModified/NumberofPages 1/OriginalDocumentID/PageUIDList<0 29955>>/PageWidthList<0 515.906>>>>>>/Resources<>/Font<>/ProcSet[/PDF/Text]/Properties<>/XObject<>>>/TrimBox[8.50394 8.50394 524.409 737.008]/Type/Page>>
endobj
20 0 obj
</LastModified/NumberofPages 1/OriginalDocumentID/PageUIDList<0 29965>>/PageWidthList<0 515.906>>>>>>/Resources<>/Font<>/ProcSet[/PDF/Text]/Properties<>/XObject<>>>/TrimBox[8.50394 8.50394 524.409 737.008]/Type/Page>>
endobj
56 0 obj
<>stream
/OC /MC0 BDC
BT
0 0 0 1 k
/Perceptual ri
/GS0 gs
/C0_0 1 Tf
7.7953 0 0 7.7953 72.9922 680.1874 Tm
<00150019>Tj
ET
EMC
/OC /MC1 BDC
q
0 g
/GS1 gs
0 TL/Fm0 Do
Q
BT
/TT0 1 Tf
9.2126 0 0 9.2126 63.7796 640.0603 Tm
[(CONFLICTS OF)37.3 ( INTERESTS)]TJ
/TT1 1 Tf
0.005 Tc 0.082 Tw 0 -1.626 Td
[( )17.6 (There are no conflicts of interests regarding this)4.9 ( )]TJ
0 Tc 0 Tw 0 -1.577 Td
[(study)64.9 (.)]TJ
/TT0 1 Tf
0 -3.105 Td
(REFERENCES)Tj
/C0_0 1 Tf
7.7953 0 0 7.7953 63.7796 568.2189 Tm
<030D02A3>Tj
/TT1 1 Tf
[(https://www)64.7 (.jata.or)55.1 (.jp/rit/ekigaku/\()]TJ
/C0_0 1 Tf
<0013001100130011>Tj
/TT1 1 Tf
(.)Tj
/C0_0 1 Tf
<0013>Tj
/TT1 1 Tf
(.)Tj
/C0_0 1 Tf
<0012001A>Tj
/TT1 1 Tf
(\))Tj
/C0_0 1 Tf
0.049 Tc -0.049 Tw 0 -1.636 Td
<030E02A3>Tj
/TT1 1 Tf
[(https://www)64.8 (.who.int/tb/publications/global_report/)]TJ
0 Tc 0 Tw 2 -1.636 Td
(en.\()Tj
/C0_0 1 Tf
<0013001100130011>Tj
/TT1 1 Tf
(.)Tj
/C0_0 1 Tf
<0013>Tj
/TT1 1 Tf
(.)Tj
/C0_0 1 Tf
<0012001A>Tj
/TT1 1 Tf
(\))Tj
/C0_0 1 Tf
-2 -1.636 Td
<030F02A3>Tj
/TT1 1 Tf
0.03 Tw [(American )18.6 (Thoracic Society; )0.5 (Centers )0.5 (for Disease )0.5 (Control )]TJ
0.045 Tw 2 -1.636 Td
[(and Prevention; Infectious Diseases Society of )55.3 (America: )]TJ
0.083 Tw 0 -1.636 Td
[(American )18.3 (Thoracic Society/Centers for Disease Control )]TJ
0.002 Tc 0 -1.636 Td
[(and )0.5 (Prevention/Infectious Diseases Society )0.5 (of )55.7 (America:)2.1 ( )]TJ
0.042 Tc 0.082 Tw 0 -1.636 Td
[(c)0.6 (o)0.5 (n)0.5 (t)0.7 (ro)0.5 (l)0.7 (l)0.6 (i)0.7 (n)0.5 (g t)0.7 (u)0.5 (be)0.7 (r)0.5 (c)0.6 (u)0.5 (l)0.6 (o)0.5 (si)0.6 (s i)0.7 (n)0.5 ( t)0.7 (h)0.5 (e)0.6 ( Un)0.5 (i)0.7 (t)0.6 (e)0.7 (d St)0.7 (a)0.6 (t)0.7 (e)0.6 (s. )55.2 (Am)0.7 ( J)41.8 ( )]TJ
0 Tc 0 Tw 0 -1.636 Td
(Respir Crit Care Med )Tj
/C0_0 1 Tf
<001200180013>Tj
/TT1 1 Tf
(: )Tj
/C0_0 1 Tf
<001200120017001A>Tj
/TT1 1 Tf
(-)Tj
/C0_0 1 Tf
<0012001300130018>Tj
/TT1 1 Tf
(, )Tj
/C0_0 1 Tf
<0013001100110016>Tj
0.031 Tc -0.031 Tw -2 -1.636 Td
<031002A3>Tj
/TT1 1 Tf
0.083 Tw [(Rieder HL, Cauthen GM, Comstock GW)18.1 ( Sinder DE)31.1 ( )]TJ
0.011 Tc 2 -1.636 Td
[(Jr)54.9 (.: Epidemiology of tuberculosis in the United States.)11.1 ( )]TJ
0 Tc 0 Tw 0 -1.636 Td
(Epidemiol Rev )Tj
/C0_0 1 Tf
<00120012>Tj
/TT1 1 Tf
(: )Tj
/C0_0 1 Tf
<0018001A>Tj
/TT1 1 Tf
(-)Tj
/C0_0 1 Tf
<001A0019>Tj
/TT1 1 Tf
(, )Tj
/C0_0 1 Tf
<0012001A0019001A>Tj
0.001 Tc -0.001 Tw -2 -1.636 Td
<031102A3>Tj
/TT1 1 Tf
0.083 Tw [(Mazurek GH, Jereb J, )18.4 (V)110.5 (ernon )55.5 (A, LoBue P)110.5 (, Goldber)17.9 (g S,)1 ( )]TJ
-0.001 Tc 0 Tw 2 -1.636 Td
[(Castro K: IGRA)54.7 ( Expert Committee; Centers for Diseases)-1.2 ( )]TJ
0.041 Tc 0.082 Tw 0 -1.636 Td
[(Cont)0.6 (rol)0.5 ( a)0.6 (nd Pre)0.5 (ve)0.6 (nt)0.6 (i)0.5 (on\(CDC\).:)0.5 ( Upda)0.5 (t)0.6 (e)0.6 (d gui)0.5 (de)0.6 (l)0.6 (i)0.5 (ne)0.6 (s)40.8 ( )]TJ
0.03 Tc 0.083 Tw 0 -1.636 Td
[(for )0.5 (suing )0.6 (Interferon )0.5 (Gamma )0.5 (release )0.6 (assays )0.5 (to )0.5 (detect)30.2 ( )]TJ
/TT2 1 Tf
0.022 Tc 0.082 Tw 0 -1.587 Td
[(Mycobacterium tuber)37.1 (culosis)]TJ
/TT1 1 Tf
12.027 -0.049 Td
[( infection- United States.)22 ( )]TJ
0 Tc 0 Tw -12.027 -1.636 Td
(MMWR Recomm Rep )Tj
/C0_0 1 Tf
<0016001A>Tj
/TT1 1 Tf
(: )Tj
/C0_0 1 Tf
<0012>Tj
/TT1 1 Tf
(-)Tj
/C0_0 1 Tf
<00130016>Tj
/TT1 1 Tf
(, )Tj
/C0_0 1 Tf
<0013001100120011>Tj
0.131 Tc -0.131 Tw -2 -1.636 Td
<031202A3>Tj
/TT1 1 Tf
0.082 Tw [(National Collaborating Centre for Chronic)131.2 ( )]TJ
0.054 Tc 2 -1.636 Td
[(C)0.5 (o)0.5 (n)0.5 (d)0.5 (i)0.7 (t)0.6 (i)0.7 (o)0.5 (n)0.5 (s\(UK\))0.5 (.)0.5 ( )18.1 (T)35.8 (u)0.5 (b)0.5 (e)0.6 (r)0.5 (c)0.7 (u)0.5 (l)0.7 (o)0.5 (si)0.7 (s:)0.7 ( C)0.5 (l)0.7 (i)0.6 (n)0.5 (i)0.7 (c)0.6 (a)0.7 (l)0.6 ( Di)0.7 (a)0.6 (g)0.5 (n)0.5 (o)0.5 (si)0.6 (s)53.9 ( )]TJ
0.07 Tc 0.083 Tw 0 -1.636 Td
[(and Management of )18.3 (T)35.1 (uberculosis, and Measures)69.8 ( )]TJ
0.062 Tc 0.082 Tw 0 -1.636 Td
[(for Its Prevention and Control. Royal College of)62 ( )]TJ
0 Tc 0 Tw 0 -1.636 Td
(Physicians\(UK\), )Tj
/C0_0 1 Tf
<0013001100110017>Tj
/TT1 1 Tf
( )Tj
/C0_0 1 Tf
0.024 Tc -0.024 Tw -2 -1.636 Td
<031302A3>Tj
/TT1 1 Tf
0.083 Tw [(Segarra F)79.7 (, Sherman DS, Rodriguez-Aguero J: Lower)24 ( )]TJ
0.011 Tc 0.082 Tw 2 -1.636 Td
[(l)0.6 (u)0.5 (ng)0.5 ( fi)0.7 (e)0.6 (l)0.6 (d t)0.6 (ub)0.5 (e)0.6 (rc)0.6 (u)0.5 (l)0.6 (osi)0.6 (s.)0.5 ( )55.1 (Am)0.6 ( R)0.5 (e)0.6 (v Re)0.7 (sp)0.5 (i)0.6 (r Di)0.6 (s )]TJ
/C0_0 1 Tf
-0.011 Tw [<0019>0.5 <0018>]TJ
/TT1 1 Tf
[(:)0.6 ( )]TJ
/C0_0 1 Tf
20.182 0 Td
<00140018>Tj
/TT1 1 Tf
0 Tc 0 Tw 1.021 0 Td
(-)Tj
/C0_0 1 Tf
0.011 Tc -0.011 Tw 0.344 0 Td
<00150011>Tj
/TT1 1 Tf
0 Tc 0 Tw 1.021 0 Td
(, )Tj
/C0_0 1 Tf
-22.568 -1.636 Td
<0012001A00170014>Tj
0.104 Tc -0.104 Tw -2 -1.636 Td
<031402A3>Tj
/TT1 1 Tf
0.083 Tw [(Hiro )37.7 (Y)128.7 (. )0.5 (Pulmonary )0.5 (tuberculosis )0.5 (and )0.5 (diabetes)103.9 ( )]TJ
0 Tc 0 Tw 2 -1.636 Td
(mellitus\(author)Tj
/C0_0 1 Tf
<029F>Tj
/TT1 1 Tf
6.36 0 Td
(s transl\). Kekkaku )Tj
/C0_0 1 Tf
<00150019>Tj
/TT1 1 Tf
(: )Tj
/C0_0 1 Tf
<001400150014>Tj
/TT1 1 Tf
(-)Tj
/C0_0 1 Tf
<00140015001A>Tj
/TT1 1 Tf
(, )Tj
/C0_0 1 Tf
<0012001A00180014>Tj
/TT1 1 Tf
( )Tj
/C0_0 1 Tf
0.021 Tc -0.021 Tw -8.36 -1.636 Td
<031502A3>Tj
/TT1 1 Tf
0.083 Tw (Komatsu H, Nagai H, Satou K, )Tj
/TT2 1 Tf
15.847 0.049 Td
(et al.)Tj
/TT1 1 Tf
0.028 Tw 2.21 -0.049 Td
[(: Association )-54.7 (of)21 ( )]TJ
0 Tc 0.054 Tw -16.057 -1.636 Td
(active pulmonary tuberculosis and malignant diseases: a )Tj
0 Tw 0 -1.636 Td
[(clinical study)64.9 (. Kekkaku )]TJ
/C0_0 1 Tf
<00180011>Tj
/TT1 1 Tf
(: )Tj
/C0_0 1 Tf
<001300190012>Tj
/TT1 1 Tf
(-)Tj
/C0_0 1 Tf
<001300190015>Tj
/TT1 1 Tf
(, )Tj
/C0_0 1 Tf
<0012001A001A0016>Tj
0.035 Tc -0.035 Tw -2 -1.636 Td
[<00120011>0.5 <02A3>]TJ
/TT1 1 Tf
0.082 Tw [(Ara)0.6 (i)0.7 ( )37 (Y)129.2 (, Sa)0.5 (t)0.7 (o R)0.5 (, Ka)0.6 (t)0.6 (su)0.5 (ra)0.6 ( )18 (T)74.8 (,)0.5 ( Ko)0.5 (m)0.6 (a)0.6 (t)0.6 (su H, Ka)0.6 (wa)0.6 (t)0.6 (a)0.6 ( K,)35 ( )]TJ
0.013 Tc 0.083 Tw 2 -1.636 Td
[(F)-0.6 (ujino )18.2 (T)73.9 (, O)-0.6 (uchi M)-0.6 (, )37.2 (Y)99.5 (akumaru K)-0.6 (: )55.2 (A)54.6 ( cas)-0.6 (e report of the)13.2 ( )]TJ
0 Tc 0.003 Tw 0 -1.636 Td
[(atypical tuberculosis associated with )55.2 (AIDS. Kekkaku )]TJ
/C0_0 1 Tf
0 Tw <00180011>Tj
/TT1 1 Tf
(: )Tj
/C0_0 1 Tf
0 -1.636 Td
<001500140012>Tj
/TT1 1 Tf
(-)Tj
/C0_0 1 Tf
<001500140018>Tj
/TT1 1 Tf
(, )Tj
/C0_0 1 Tf
<0012001A001A0016>Tj
0.069 Tc -0.069 Tw -2 -1.636 Td
<0012001202A3>Tj
/TT1 1 Tf
0.083 Tw [(Y)110.3 (u )37.2 (YH)-0.6 (, Liao CC, Hsu )18.1 (WH)-0.6 (, Chen HJ)-0.6 (, Liao )18.2 (WC,)69 ( )]TJ
0.026 Tc 2 -1.636 Td
[(Muo )0.5 (CH, )0.5 (Sung FC, Chen )0.5 (CY)91.6 (: Increased )0.5 (lung )0.5 (cancer)26 ( )]TJ
0.037 Tc 0 -1.636 Td
[(risk among patients with pulmonary tuberculosis: a)37.1 ( )]TJ
0 Tc 0 Tw 0 -1.636 Td
[(population cohort study)65 (. J )18.1 (Thorac Oncol )]TJ
/C0_0 1 Tf
<0017>Tj
/TT1 1 Tf
(: )Tj
/C0_0 1 Tf
<00140013>Tj
/TT1 1 Tf
(-)Tj
/C0_0 1 Tf
<00140018>Tj
/TT1 1 Tf
(, )Tj
/C0_0 1 Tf
<0013001100120012>Tj
0.016 Tc -0.016 Tw 25.182 73.364 Td
<0012001302A3>Tj
/TT1 1 Tf
0.083 Tw [(T)69.8 (amura )55.4 (A, Hebisawa )55.4 (A, Masuda K, )]TJ
/TT2 1 Tf
17.517 0.049 Td
(et al.)Tj
/TT1 1 Tf
2.179 -0.049 Td
[(: Coexisting)16 ( )]TJ
0.039 Tc 0.082 Tw -17.696 -1.636 Td
[(l)0.5 (ung ca)0.5 (nce)0.5 (r a)0.5 (nd ac)0.5 (ti)0.5 (ve pul)0.5 (m)0.5 (onary m)0.5 (ycoba)0.5 (ct)0.5 (eri)0.5 (osi)0.5 (s.)39 ( )]TJ
0 Tc 0 Tw 0 -1.636 Td
(Nihon Kokyuki Gakkai Zasshi )Tj
/C0_0 1 Tf
<00150016>Tj
/TT1 1 Tf
(: )Tj
/C0_0 1 Tf
<001400190013>Tj
/TT1 1 Tf
(-)Tj
/C0_0 1 Tf
<0014001A0014>Tj
/TT1 1 Tf
(, )Tj
/C0_0 1 Tf
<0013001100110018>Tj
-2 -1.636 Td
<0012001402A3>Tj
/TT1 1 Tf
1.96 0 Td
(Kourbeti IS, Ziakas PD, Mylonakis E: Biologic therapies )Tj
0.034 Tc 0.083 Tw 0.04 -1.636 Td
[(in rheumatoid arthritis and the risk of opportunistic)34.2 ( )]TJ
0.019 Tc 0 -1.636 Td
(infections: a meta-analysis. Clin Infect Dis )Tj
/C0_0 1 Tf
-0.019 Tw <00160019>Tj
/TT1 1 Tf
(: )Tj
/C0_0 1 Tf
20.408 0 Td
<001200170015001A>Tj
/TT1 1 Tf
0 Tc 0 Tw (-)Tj
/C0_0 1 Tf
-20.408 -1.636 Td
<0012001700160018>Tj
/TT1 1 Tf
(, )Tj
/C0_0 1 Tf
<0013001100120015>Tj
-2 -1.636 Td
<0012001502A3>Tj
/TT1 1 Tf
0.068 Tw [(Dixon )17.8 (WG, Symmons DP)110.7 (, Lunt M, )17.8 (W)80.3 (atson KD, Hyrich )]TJ
0.065 Tc 0.083 Tw 2 -1.636 Td
[(KL; British Society for Rheumatology Biologics)64.9 ( )]TJ
0.003 Tc 0 -1.636 Td
[(Register )0.5 (Control )0.5 (Centre )0.5 (Consortium )0.5 (Silman )55.7 (AJ; )0.5 (British)3 ( )]TJ
0.013 Tc 0.082 Tw 0 -1.636 Td
[(Society for Rheumatology Biologics Register: Serious)12.9 ( )]TJ
0.034 Tc 0 -1.636 Td
[(i)0.5 (nfe)0.5 (c)0.5 (ti)0.5 (on fol)0.5 (l)0.5 (owi)0.5 (ng ant)0.5 (i)0.5 (-t)0.5 (um)0.5 (or nec)0.5 (rosi)0.5 (s fa)0.5 (c)0.5 (t)0.5 (or a)0.5 (l)0.5 (pha)34.2 ( )]TJ
0.025 Tc 0.083 Tw 0 -1.636 Td
[(therapy in patients )0.5 (with )0.5 (rheumatoid )0.5 (arthritis: )0.5 (lessons)24.9 ( )]TJ
0.052 Tc 0.082 Tw 0 -1.636 Td
[(f)0.5 (r)0.5 (o)0.6 (m)0.6 ( i)0.7 (n)0.5 (t)0.7 (e)0.7 (r)0.5 (p)0.5 (r)0.5 (e)0.7 (t)0.7 (i)0.7 (n)0.5 (g)0.5 ( d)0.5 (a)0.7 (t)0.7 (a)0.6 ( f)0.5 (r)0.5 (o)0.5 (m)0.7 ( o)0.6 (b)0.5 (se)0.7 (r)0.6 (v)0.5 (a)0.7 (t)0.6 (i)0.7 (o)0.6 (n)0.5 (a)0.7 (l)0.7 ( st)0.7 (u)0.6 (d)0.5 (i)0.7 (e)0.7 (s.)52 ( )]TJ
0 Tc 0 Tw 0 -1.636 Td
(Arthritis Rheum )Tj
/C0_0 1 Tf
<00160017>Tj
/TT1 1 Tf
(: )Tj
/C0_0 1 Tf
<00130019001A0017>Tj
/TT1 1 Tf
(-)Tj
/C0_0 1 Tf
<0013001A00110015>Tj
/TT1 1 Tf
(, )Tj
/C0_0 1 Tf
<0013001100110018>Tj
0.014 Tc -0.014 Tw -2 -1.636 Td
<0012001602A3>Tj
/TT1 1 Tf
0.082 Tw [(Galloway JB, Hyrich KL, Mercer LK, Dixon )17.7 (WG, Fu)14 ( )]TJ
0 Tc 0.038 Tw 2 -1.636 Td
[(B, Ustianowski )55.3 (AP)110.6 (, )18.2 (W)80.2 (atson KD, Lunt M, Symmons DP; )]TJ
0.081 Tw 0 -1.636 Td
(BSRBR Control Centre Consortium; British Society for )Tj
0.083 Tw 0 -1.636 Td
[(Rheumatology Biologics Register)54.8 (.: )55.3 (Anti-TNF therapy is )]TJ
0.041 Tw 0 -1.636 Td
[(associated )0.5 (with )0.5 (an increased risk of serious )0.5 (infections )0.5 (in )]TJ
0.006 Tc 0.082 Tw 0 -1.636 Td
[(patients with rheumatoid arthritis especially in the first)6.1 ( )]TJ
/C0_0 1 Tf
0 Tc 0 Tw 0 -1.636 Td
<0017>Tj
/TT1 1 Tf
0.003 Tc 0.083 Tw 0.503 0 Td
[( )0.5 (months )0.5 (of )0.5 (treatment: )0.5 (updated )0.5 (results )0.5 (from )0.5 (the )0.5 (British)3 ( )]TJ
0.046 Tc 0.082 Tw -0.503 -1.636 Td
[(Society for Rheumatology Biologics Register with)46 ( )]TJ
0.005 Tc 0 -1.636 Td
[(special emphasis on risks in the elderly)65.2 (. Rheumatology)5 ( )]TJ
/C0_0 1 Tf
0 Tc 0 Tw 0 -1.636 Td
<00160011>Tj
/TT1 1 Tf
(: )Tj
/C0_0 1 Tf
<001200130015>Tj
/TT1 1 Tf
(-)Tj
/C0_0 1 Tf
<001200140012>Tj
/TT1 1 Tf
(, )Tj
/C0_0 1 Tf
<0013001100120012>Tj
0.034 Tc -0.034 Tw -2 -1.636 Td
<0012001702A3>Tj
/TT1 1 Tf
0.082 Tw [(Ja)0.5 (pa)0.5 (n Col)0.6 (le)0.5 (ge)0.5 ( of Rhe)0.5 (um)0.5 (a)0.5 (t)0.5 (ol)0.5 (ogy:)0.5 ( Gui)0.5 (de)0.5 (l)0.5 (i)0.5 (ne)0.5 (s for t)0.5 (he)34.1 ( )]TJ
0.043 Tc 2 -1.636 Td
[(management of )-0.6 (rheumatoid arthritis )]TJ
/C0_0 1 Tf
-0.043 Tw 16.443 0 Td
<0013001100120015>Tj
/TT1 1 Tf
0.082 Tw [(, Medical)43.2 ( )]TJ
0 Tc 0 Tw -16.443 -1.636 Td
(review co.: )Tj
/C0_0 1 Tf
<0012>Tj
/TT1 1 Tf
(-)Tj
/C0_0 1 Tf
<001300140013>Tj
/TT1 1 Tf
(, )Tj
/C0_0 1 Tf
<0013001100120015>Tj
/TT1 1 Tf
(\(Article in Japanese\))Tj
/C0_0 1 Tf
0.017 Tc -0.017 Tw -2 -1.636 Td
<0012001802A3>Tj
/TT1 1 Tf
0.083 Tw [(The Japanese Society for )18.2 (T)34.9 (uberculosis: )18.2 (T)34.9 (reatment for)17 ( )]TJ
0.013 Tc 0.082 Tw 2 -1.636 Td
[(l)0.7 (a)0.7 (t)0.7 (e)0.7 (n)0.5 (t)0.7 ( t)0.7 (u)0.5 (b)0.6 (e)0.7 (r)0.5 (c)0.6 (u)0.6 (l)0.7 (o)0.5 (si)0.7 (s i)0.7 (n)0.6 (f)0.5 (e)0.7 (c)0.7 (t)0.7 (i)0.6 (o)0.6 (n)0.5 (.)0.5 ( Ke)0.7 (k)0.5 (k)0.6 (a)0.6 (k)0.6 (u)0.5 ( )]TJ
/C0_0 1 Tf
-0.013 Tw [<0019>0.6 <0019>]TJ
/TT1 1 Tf
0 Tc 0 Tw 17.309 0 Td
(\()Tj
/C0_0 1 Tf
0.345 0 Td
<0016>Tj
/TT1 1 Tf
0.013 Tc -0.013 Tw 0.512 0 Td
[(\))0.5 (:)0.7 ( )]TJ
/C0_0 1 Tf
0.981 0 Td
[<0015>0.5 <001A>0.6 <0018>]TJ
/TT1 1 Tf
0 Tc 0 Tw 1.537 0 Td
(-)Tj
/C0_0 1 Tf
0.013 Tc -0.013 Tw 0.345 0 Td
[<0016>0.5 <0012>0.6 <0013>]TJ
/TT1 1 Tf
0 Tc 0 Tw 1.537 0 Td
(, )Tj
/C0_0 1 Tf
-22.568 -1.636 Td
<0013001100120014>Tj
/TT1 1 Tf
(\(Article in Japanese\))Tj
/C0_0 1 Tf
0.01 Tc -0.01 Tw -2 -1.636 Td
<0012001902A3>Tj
/TT1 1 Tf
0.082 Tw [(Centers for Diseases Control and Prevention: )17.6 (T)70.1 (ar)18.1 (geted)10 ( )]TJ
0.018 Tc 0.083 Tw 2 -1.636 Td
[(tuberculin tes)-0.6 (ting and treatment of latent tuberculos)-0.6 (is)17.9 ( )]TJ
0 Tc 0 Tw 0 -1.636 Td
(infection. MMWR Recomm Rep. )Tj
/C0_0 1 Tf
<0015001A>Tj
/TT1 1 Tf
(: )Tj
/C0_0 1 Tf
<0012>Tj
/TT1 1 Tf
(-)Tj
/C0_0 1 Tf
<00160015>Tj
/TT1 1 Tf
(, )Tj
/C0_0 1 Tf
<0013001100110011>Tj
0.034 Tc -0.034 Tw -2 -1.636 Td
[<0012>0.5 <001A02A3>]TJ
/TT1 1 Tf
0.082 Tw 2.101 0 Td
[(Ha)0.6 (g)0.5 (i)0.6 (wa)0.6 (ra)0.6 ( )18 (T)74.9 (, )55.2 (Am)0.6 (a)0.6 (no)0.5 ( K,)0.5 ( Su)0.5 (g)0.5 (i)0.6 (m)0.6 (u)0.5 (ra)0.6 ( D, Iso)0.5 (ga)0.6 (i)0.7 ( N,)0.5 ( )55.1 (Ara)0.6 (i)34.2 ( )]TJ
0.023 Tc 0.083 Tw -0.101 -1.636 Td
[(M)-0.6 (, F)-0.6 (ukutake K)-0.6 (, K)-0.6 (ojima H)-0.6 (, S)-0.6 (himada H)-0.6 (: M)-0.6 (ass)-0.6 (ive and)23 ( )]TJ
0 Tc 0.012 Tw 0 -1.636 Td
(progressive hepatosplenomegaly caused by disseminated )Tj
0.059 Tc 0.083 Tw 0 -1.636 Td
[(nontuberculous )0.6 (mycobacteriosis )0.5 (in )0.5 (a )0.6 (patient )0.6 (with)59.1 ( )]TJ
0.032 Tc 0.082 Tw 0 -1.636 Td
(acquired immunodeficiency syndrome. Kekkaku )Tj
/C0_0 1 Tf
-0.032 Tw <00180011>Tj
/TT1 1 Tf
0 Tc 0 Tw (: )Tj
/C0_0 1 Tf
0 -1.636 Td
<001500130014>Tj
/TT1 1 Tf
(-)Tj
/C0_0 1 Tf
<00150013001A>Tj
/TT1 1 Tf
(, )Tj
/C0_0 1 Tf
<0012001A001A0016>Tj
-2 -1.636 Td
<0013001102A3>Tj
/TT1 1 Tf
1.911 0 Td
[(Komiya K, )55.1 (Ariga H, Nagai H, )18.1 (T)69.9 (eramoto S, Kurashima )55.2 (A, )]TJ
0.008 Tc 0.083 Tw 0.089 -1.636 Td
[(S)-0.6 (hoji S)-0.6 (, N)-0.6 (akajima )37.1 (Y)91.2 (: Impact of peripheral lymphocyte)8.2 ( )]TJ
0 Tc 0.058 Tw 0 -1.636 Td
(count on the sensitivity of )Tj
/C0_0 1 Tf
0 Tw <0013>Tj
/TT1 1 Tf
0.058 Tw ( IFN-gamma release assays, )Tj
0.047 Tc 0.082 Tw 0 -1.636 Td
[(QFT)92.3 (-G, and E)0.5 (LISPOT)74.7 (, i)0.5 (n pat)0.5 (ie)0.5 (nt)0.5 (s wit)0.5 (h pulmonary)47 ( )]TJ
0 Tc 0 Tw 0 -1.636 Td
(tuberculosis. Intern Med )Tj
/C0_0 1 Tf
<0015001A>Tj
/TT1 1 Tf
(: )Tj
/C0_0 1 Tf
<001200190015001A>Tj
/TT1 1 Tf
(-)Tj
/C0_0 1 Tf
<0012001900160016>Tj
/TT1 1 Tf
(, )Tj
/C0_0 1 Tf
<0013001100120011>Tj
ET
EMC
endstream
endobj
34 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
BT
0 0 0 1 k
/Perceptual ri
/GS0 gs
/TT0 1 Tf
0 Tc 0 Tw 0 Ts 100 Tz 0 Tr 7.7953 0 0 7.7953 224.896 680.1874 Tm
(Kawasaki Medical Journal)Tj
ET
endstream
endobj
57 0 obj
<>
endobj
58 0 obj
<>
endobj
59 0 obj
<>stream
H|w\TWg3C"mx3cY]Ȯn"*%
$6Tlذ]l]P3EW13cX{9{A&$tѴEp'#&d@\JlZcz -n4k.~YiSRz4x<&)wZ(9 $E}Bti+m{ziuہ_ơ) t xU7KK
Q?mxBf
}0;Ԛr C/-EoDM
KVHڛpb-г[#atUNRg %fϑwCD
aTEѸNI+NS?f`Pu֫oQ&sh7KDf[l:m}oQ ]v]Ϯ>{}һOO?@,>OH8hpҐ䔡iÆHbc~ո_3!&N <.<1|HxjeZ9tD9:9>tr**W}PyU3ԙpV*'K|
4&MM&Hc,iB*^jkhcro9V,OgeSbNɆb3!!!ϔڊQTsd*;r]y0hL7'L9o8Nu!՜_s27r|uN'+{o8%' N"Ql1[&Y6Y^o&8Qap*UELstf9n'B])`w-F"ivoa.%Ǝ337ȭȭX^1XV_h*+ZV::ڢl"m-ml
mf[=[v}]-,k*2uf5[M;cn\$"J2hƈ+HP[wEw~V0: